Janux Therapeutics vs Pyxis Oncology
JANX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JANX and PYXS compare
Janux Therapeutics is the larger company, worth 5.3 times as much as Pyxis Oncology ($695M against $132M).
Janux Therapeutics scores higher on the StockData Score (12 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JANX | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | $695M | $132M |
| Share price | $11.37 | $1.58 |
| Change, 1 year | −60.1% | −63.8% |
| Change, 5 years | −36.4% | −87.8% |
| Beta (5Y) | 1.60 | 1.61 |
| Employees | 109 | 56 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 29.8× | – |
| P/B | 0.8× (better) | 3.2× |
| FCF yield | −7.8% | – |
| Fair value | $16.54 | – |
| Margin of safety | 31.3% | – |
| Growth | ||
| Revenue growth (TTM) | 133% | – |
| Profitability | ||
| Operating margin | −599% | – |
| Net margin | −429% | – |
| FCF margin | −233% | – |
| Return on equity | −10.6% (better) | −158% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 17.69 (better) | 2.96 |
| Altman Z-score | 5.85 (better) | −10.32 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 40.9% |
| Held by insiders | 21.3% | 20.4% |
| Insider net buying, 12 months | −$457K | −$107K (better) |
| Short interest, % of float | 11.1% | 6.8% |
Go deeper
- JANX stock overview
- JANX income statement
- JANX valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.